GlassScriptPhysician profile
Kelley W Smith
NPI 1770535080
$4,871.02
in general payments reported to CMS, 2019-2025
28 companies · $746 in 2025
The $746 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $531 · 2021: $756 · 2022: $501 · 2023: $417 · 2024: $695 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,245.67 | 2019-2025 | |
| Boston Scientific Corporation | $660.12 | 2019-2025 | Synergy, Avvigo Guidance System, Accolade Sr |
| Amgen INC. | $586.18 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $381.40 | 2019-2025 | Lifevest |
| Pfizer INC. | $328.50 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $267.18 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $231.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $208.68 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $185.07 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $91.30 | 2022-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $85.61 | 2021-2023 | |
| Medtronic Vascular, INC. | $81.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.18 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.44 | 2019-2022 | |
| Akcea Therapeutics, INC. | $45.50 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $43.78 | 2024 | Impella |
| Esperion Therapeutics, INC. | $41.62 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $40.30 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $38.20 | 2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $37.01 | 2025 | Amvuttra |
| Philips North America LLC | $28.38 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Cardiva Medical, INC. | $23.61 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Csl Behring | $18.23 | 2021 | |
| Scpharmaceuticals INC. | $18.00 | 2023 | |
| Astellas Pharma US INC | $15.92 | 2020 | |
| Chiesi USA, INC. | $15.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.28 | 2019 | |
| Amarin Pharma, INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.